<code id='4A114DEDB3'></code><style id='4A114DEDB3'></style>
    • <acronym id='4A114DEDB3'></acronym>
      <center id='4A114DEDB3'><center id='4A114DEDB3'><tfoot id='4A114DEDB3'></tfoot></center><abbr id='4A114DEDB3'><dir id='4A114DEDB3'><tfoot id='4A114DEDB3'></tfoot><noframes id='4A114DEDB3'>

    • <optgroup id='4A114DEDB3'><strike id='4A114DEDB3'><sup id='4A114DEDB3'></sup></strike><code id='4A114DEDB3'></code></optgroup>
        1. <b id='4A114DEDB3'><label id='4A114DEDB3'><select id='4A114DEDB3'><dt id='4A114DEDB3'><span id='4A114DEDB3'></span></dt></select></label></b><u id='4A114DEDB3'></u>
          <i id='4A114DEDB3'><strike id='4A114DEDB3'><tt id='4A114DEDB3'><pre id='4A114DEDB3'></pre></tt></strike></i>

          knowledge

          knowledge

          author:entertainment    Page View:7593
          the shape of a medical note connected by dots and lines — health tech coverage from STAT
          Adobe

          In recent months, the federal government has repeatedly told Medicare Advantage insurers that they cannot use artificial intelligence or algorithms to deny medical services the government routinely covers.

          But in finalizing a rule to that effect, it also stepped into a thicket of questions from insurers about a technology that is especially difficult to pin down: What is AI? Can it be used at all to make decisions about the coverage of older patients? If so, how?

          advertisement

          This week, the federal agency that oversees Medicare sought to boil it all down into a simple directive: Put the circumstances of the individual patient first, and your algorithm second.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi
          Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          Merck drug for rare lung condition set for approval in U.S.

          AdobeTheFoodandDrugAdministrationisexpectedtoapproveMerck’sdrugtotreatararelungdisordercalledpulmona